Keeping expanded access programs in context

被引：1
|
作者：
Caress, James B. [1 ,2 ]
机构：
[1] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC USA
[2] Wake Forest Sch Med, Dept Neurol, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA
来源：
MUSCLE & NERVE | 2023年 / 67卷 / 05期
关键词：
amyotrophic lateral sclerosis; biomarker; clinical trial; expanded access program; FDA approval; AMYOTROPHIC-LATERAL-SCLEROSIS;
D O I：
10.1002/mus.27802
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：337 / 338
页数：2
相关论文
共 50 条
  • [1] EXPANDED ACCESS PROGRAMS AS A SOURCE OF COGNITIVE DATA
    Dryla, Olga
    DIAMETROS, 2023, 20 (78): : 2 - 15
  • [2] FDA Expanded Access Programs for Experimental Medicines
    Nightingale, Stuart L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (12): : 1296 - 1296
  • [3] Characterizing expanded access and compassionate use programs for experimental drugs
    Miller J.E.
    Ross J.S.
    Moch K.I.
    Caplan A.L.
    BMC Research Notes, 10 (1)
  • [4] Results from Expanded Access Programs: A Review of Academic Literature
    Polak, Tobias B. B.
    Cucchi, David G. J.
    Schelhaas, Jasmin
    Ahmed, Syed S. S.
    Khoshnaw, Naima
    van Rosmalen, Joost
    Uyl-de Groot, Carin A. A.
    DRUGS, 2023, 83 (09) : 795 - 805
  • [5] Results from Expanded Access Programs: A Review of Academic Literature
    Tobias B. Polak
    David G. J. Cucchi
    Jasmin Schelhaas
    Syed S. Ahmed
    Naima Khoshnaw
    Joost van Rosmalen
    Carin A. Uyl-de Groot
    Drugs, 2023, 83 : 795 - 805
  • [6] Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors
    Mitchell Klopfenstein
    Luann E. Van Campen
    Timothy Garnett
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 352 - 358
  • [7] Barriers to implementing expanded access programs in oncology: A multidisciplinary perspective
    Fu, Sherry
    Muquith, Maishara
    Williams, Erin Fenske
    Anderson, Larry D., Jr.
    Zhang, Tian
    Beg, Shaalan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors
    Klopfenstein, Mitchell
    Van Campen, Luann E.
    Garnett, Timothy
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (03) : 352 - 358
  • [9] Is it time to rethink the expanded-access programs for HIV infection?
    Amorosa, Valerianna
    Tebas, Pablo
    JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (07): : 974 - 977
  • [10] Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein, M. E. Blair
    Berglund, Jelena P.
    Weatherwax, Kevin
    Gerber, David E.
    Adamo, Joan E.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2015, 8 (05): : 526 - 532
12345